Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Igal Kushnir"'
Autor:
Jennifer Leigh, Danial Qureshi, Ewa Sucha, Roshanak Mahdavi, Igal Kushnir, Luke T. Lavallée, Dominick Bosse, Colleen Webber, Peter Tanuseputro, Michael Ong
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5569-5579 (2023)
Abstract Introduction Life‐prolonging therapies (LPTs) are rapidly evolving for the treatment of advanced prostate cancer, although factors associated with real‐world uptake are not well characterized. Methods In this cohort of prostate‐cancer
Externí odkaz:
https://doaj.org/article/bc6ea2bab9004d078643679d45ffd48b
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1912-1921 (2023)
Abstract Purpose Infertility is a critical late toxicity that impacts adolescent and young adult (AYA, ages 15–39 years) cancer survivors. International oncology societies recommend discussing fertility preservation (FP) for all AYA patients, regar
Externí odkaz:
https://doaj.org/article/eb8e8a9e17b247cd98774334c5f89633
Autor:
Keren Rouvinov, Eran Levanon, Avivit Peer, Michal Sarfaty, David Sarid, Victoria Neiman, Eduard Grikshtas, Eli Rosenbaum, Igal Kushnir, Barak Talmor, Michael Friger, Yonaton Zarbiv, Eli Gez, Hadas Dresler, Walid Shalata, Amichay Meirovitz, Noa Shani Shrem, Alexander Yakobson, Wilmosh Mermershtain, Daniel Keizman
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundErdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical
Externí odkaz:
https://doaj.org/article/5d97724776e04b738ec6fc3ae439db56
Autor:
Daniel Keizman, Moshe Frenkel, Avivit Peer, Eli Rosenbaum, David Sarid, Ilan Leibovitch, Roy Mano, Ofer Yossepowitch, Ido Wolf, Ravit Geva, David Margel, Keren Rouvinov, Anat Stern, Hadas Dresler, Igal Kushnir, Isaac Eliaz
Publikováno v:
Nutrients, Vol 15, Iss 16, p 3533 (2023)
The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol®-Modified citrus pectin
Externí odkaz:
https://doaj.org/article/38710bb6eed943709780a09867d92b6b
Autor:
Daniel Keizman, Moshe Frenkel, Avivit Peer, Igal Kushnir, Eli Rosenbaum, David Sarid, Ilan Leibovitch, Roy Mano, Ofer Yossepowitch, David Margel, Ido Wolf, Ravit Geva, Hadas Dresler, Keren Rouvinov, Noa Rapoport, Isaac Eliaz
Publikováno v:
Nutrients, Vol 13, Iss 12, p 4295 (2021)
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus pectin (PectaSol®, P-MCP), a dietary polysaccharide, is an established antagonist of galectin-3, a carbohydrate-binding
Externí odkaz:
https://doaj.org/article/e35f3b4284a240c6bc471f263e968b3b
Publikováno v:
Cancer Medicine. 12:1912-1921
Infertility is a critical late toxicity that impacts adolescent and young adult (AYA, ages 15-39 years) cancer survivors. International oncology societies recommend discussing fertility preservation (FP) for all AYA patients, regardless of stage or p
Autor:
Alexander W. Wyatt, Kim N. Chi, Matti Annala, Sebastien Hotte, Cristiano Ferrario, Igal Kushnir, Ladan Fazli, Daniel Khalaf, Yulia Loktionova, Kevin Beja, Gillian Vandekerkhove, Andrew J. Murtha, Sinja Taavitsainen, Elena Schönlau, Evan W. Warner, Gang Wang, Cameron Herberts, Simon Y.F. Fu, Elie Ritch
Supplementary Figure 12. Swimmer plot showing overall patient survival from initial cancer diagnosis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac227298eaf265c7c5683d4095b9228d
https://doi.org/10.1158/1078-0432.22474119.v1
https://doi.org/10.1158/1078-0432.22474119.v1
Autor:
Alexander W. Wyatt, Kim N. Chi, Matti Annala, Sebastien Hotte, Cristiano Ferrario, Igal Kushnir, Ladan Fazli, Daniel Khalaf, Yulia Loktionova, Kevin Beja, Gillian Vandekerkhove, Andrew J. Murtha, Sinja Taavitsainen, Elena Schönlau, Evan W. Warner, Gang Wang, Cameron Herberts, Simon Y.F. Fu, Elie Ritch
Purpose:DNA mismatch repair defects (MMRd) and tumor hypermutation are rare and under-characterized in metastatic prostate cancer (mPC). Furthermore, because hypermutated MMRd prostate cancers can respond to immune checkpoint inhibitors, there is an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::821bdea13eeb3ba454b217fa2c652b7c
https://doi.org/10.1158/1078-0432.c.6528684.v1
https://doi.org/10.1158/1078-0432.c.6528684.v1
Autor:
Alexander W. Wyatt, Kim N. Chi, Matti Annala, Sebastien Hotte, Cristiano Ferrario, Igal Kushnir, Ladan Fazli, Daniel Khalaf, Yulia Loktionova, Kevin Beja, Gillian Vandekerkhove, Andrew J. Murtha, Sinja Taavitsainen, Elena Schönlau, Evan W. Warner, Gang Wang, Cameron Herberts, Simon Y.F. Fu, Elie Ritch
Supplementary Table 1: Somatic mutation count across all samples within meta-cohort. Counts of mutations in all ctDNA positive samples. 95th and 90th percentile are highlighted. Samples are named as a function of their relative mutation count. Supple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293767118f38763a57a1fa4f76eaf160
https://doi.org/10.1158/1078-0432.22474089
https://doi.org/10.1158/1078-0432.22474089
Autor:
Jennifer Leigh, Danial Qureshi, Ewa Sucha, Roshanak Mahdavi, Igal Kushnir, Luke T. Lavallée, Dominick Bosse, Colleen Webber, Peter Tanuseputro, Michael Ong
Publikováno v:
Cancer medicineREFERENCES.
Life-prolonging therapies (LPTs) are rapidly evolving for the treatment of advanced prostate cancer, although factors associated with real-world uptake are not well characterized.In this cohort of prostate-cancer decedents, we analyzed factors associ